Usefulness of apolipoprotein B-depleted serum in cholesterol efflux capacity assays using immobilized liposome-bound gel beads.


Journal

Bioscience reports
ISSN: 1573-4935
Titre abrégé: Biosci Rep
Pays: England
ID NLM: 8102797

Informations de publication

Date de publication:
30 04 2019
Historique:
received: 31 01 2019
revised: 08 03 2019
accepted: 12 03 2019
pubmed: 15 3 2019
medline: 10 4 2020
entrez: 15 3 2019
Statut: epublish

Résumé

Cholesterol efflux capacity (CEC) in atherosclerotic lesions is the main anti-atherosclerotic function of high-density lipoprotein (HDL). In recent studies, apolipoprotein (apo) B-depleted serum (BDS) obtained with the polyethylene glycol (PEG) precipitation method is used as a cholesterol acceptor (CA) substitution for HDL isolated by ultracentrifugation. However, the suitability of BDS as a CA is controversial. In the present study, CEC obtained from BDS (BDS-CEC) was evaluated based on a parameter, defined as whole-CEC, which was calculated by multiplying CEC obtained using fixed amounts of HDL by cholesterol concentration to HDL-cholesterol (HDL-C) levels in the serum. Significant correlation (r = 0.633) was observed between both CECs. To eliminate systematic errors from possible contamination with serum proteins and low-density lipoprotein (LDL) or very-LDL (VLDL) in BDS-CEC, the deviation of each CEC-BDS from the regression equation was compared with serum protein, LDL, and triglyceride (TG) levels. No correlation was observed between the deviation and the levels of each of these serum components, indicating that the deviations do not derive from systematic error. Further, to evaluate the effects of serum protein on the results, we measured BDS-CEC of reconstituted serum samples prepared using combinations of five levels of serum proteins with five levels of HDL-C. No significant change in BDS-CEC was observed in any combination. These results indicate that BDS-CEC reflects not only the function of HDL but also its concentration in serum.

Identifiants

pubmed: 30867253
pii: BSR20190213
doi: 10.1042/BSR20190213
pmc: PMC6443949
pii:
doi:

Substances chimiques

Apolipoproteins B 0
Cholesterol, HDL 0
Lipoproteins, LDL 0
Lipoproteins, VLDL 0
Liposomes 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 The Author(s).

Références

Clin Chim Acta. 2014 Feb 15;429:111-22
pubmed: 24333390
J Lipid Res. 2006 Mar;47(3):605-13
pubmed: 16327021
J Biol Chem. 2005 Oct 28;280(43):35890-5
pubmed: 16120612
N Engl J Med. 2014 Dec 18;371(25):2383-93
pubmed: 25404125
J Lipid Res. 2017 Mar;58(3):600-606
pubmed: 28049656
World J Methodol. 2014 Sep 26;4(3):163-88
pubmed: 25332915
J Clin Invest. 1955 Sep;34(9):1345-53
pubmed: 13252080
Atherosclerosis. 2008 Apr;197(2):732-9
pubmed: 17709109
Atherosclerosis. 2013 Dec;231(2):405-10
pubmed: 24267259
Cell Metab. 2013 Aug 6;18(2):225-38
pubmed: 23931754
Arterioscler Thromb Vasc Biol. 2018 Nov;38(11):2750-2754
pubmed: 30354236
N Engl J Med. 2007 Sep 27;357(13):1301-10
pubmed: 17898099
J Clin Invest. 1951 Oct;30(10):1071-81
pubmed: 14888685
Circulation. 2017 Jun 20;135(25):2494-2504
pubmed: 28450350
J Lipid Res. 1981 Feb;22(2):339-58
pubmed: 6787159
N Engl J Med. 2011 Jan 13;364(2):127-35
pubmed: 21226578
Scand J Clin Lab Invest. 1976 May;36(3):265-8
pubmed: 181836
Biosci Rep. 2018 Apr 13;38(2):
pubmed: 29545317
Lancet. 2010 Jul 31;376(9738):333-9
pubmed: 20655105
J Lipid Res. 2008 Nov;49(11):2312-22
pubmed: 18622028
Biol Chem. 2019 Jan 28;400(2):209-218
pubmed: 30210053

Auteurs

Yuna Horiuchi (Y)

Analytical Laboratory Chemistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.

Ryunosuke Ohkawa (R)

Analytical Laboratory Chemistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan ohkawa.alc@tmd.ac.jp.

Shao-Jui Lai (SJ)

Analytical Laboratory Chemistry, Graduate School of Health Care Science, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.

Shitsuko Shimano (S)

Clinical Laboratory, Medical Hospital, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.

Michio Hagihara (M)

Clinical Laboratory, Medical Hospital, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.

Shuji Tohda (S)

Clinical Laboratory, Medical Hospital, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.

Takahiro Kameda (T)

Department of Medical Technology, School of Health Sciences, Tokyo University of Technology, 5-23-22 Nishikamata, Ota-ku, Tokyo 144-8535, Japan.

Minoru Tozuka (M)

Analytical Laboratory Chemistry, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH